Response Genetics Stock Analysis
| RGDXQ Stock | USD 0.0001 0.00 0.00% |
Response Genetics' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Response Genetics' financial risk is the risk to Response Genetics stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Response Genetics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Response Genetics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Response Genetics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Response Genetics is said to be less leveraged. If creditors hold a majority of Response Genetics' assets, the Company is said to be highly leveraged.
Response Genetics is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Response Genetics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Response Genetics is worth, separate from its market price. There are two main types of Response Genetics' stock analysis: fundamental analysis and technical analysis.
The Response Genetics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Response |
Response Pink Sheet Analysis Notes
The company recorded a loss per share of 0.37. Response Genetics had not issued any dividends in recent years. Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. RESPONSE GENETICS operates under Diagnostics Research classification in the United States and is traded on PNK Exchange. It employs 96 people.The quote for Response Genetics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Response Genetics contact the company at 323-224-3900 or learn more at https://www.responsegenetics.com.Response Genetics Investment Alerts
| Response Genetics generated a negative expected return over the last 90 days | |
| Response Genetics has some characteristics of a very speculative penny stock | |
| Response Genetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 18.04 M. Net Loss for the year was (20.18 M) with profit before overhead, payroll, taxes, and interest of 6.23 M. | |
| Response Genetics has accumulated about 1.73 M in cash with (13.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Response Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 116. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Response Genetics's market, we take the total number of its shares issued and multiply it by Response Genetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Response Profitablity
The company has Profit Margin (PM) of (0.86) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.82) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.82.Technical Drivers
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Response Genetics, as well as the relationship between them.Response Genetics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Response Genetics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Response Genetics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Response Genetics Outstanding Bonds
Response Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Response Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Response bonds can be classified according to their maturity, which is the date when Response Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US76120HAA59 Corp BondUS76120HAA59 | View | |
| US76120HAC16 Corp BondUS76120HAC16 | View |
Response Genetics Debt to Cash Allocation
Response Genetics has accumulated 10.94 M in total debt. Response Genetics has a current ratio of 1.75, which is within standard range for the sector. Debt can assist Response Genetics until it has trouble settling it off, either with new capital or with free cash flow. So, Response Genetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Response Genetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Response to invest in growth at high rates of return. When we think about Response Genetics' use of debt, we should always consider it together with cash and equity.Response Genetics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Response Genetics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Response Genetics, which in turn will lower the firm's financial flexibility.Response Genetics Corporate Bonds Issued
About Response Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Response Genetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Response shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Response Genetics. By using and applying Response Pink Sheet analysis, traders can create a robust methodology for identifying Response entry and exit points for their positions.
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. RESPONSE GENETICS operates under Diagnostics Research classification in the United States and is traded on PNK Exchange. It employs 96 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Response Genetics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Additional Tools for Response Pink Sheet Analysis
When running Response Genetics' price analysis, check to measure Response Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Response Genetics is operating at the current time. Most of Response Genetics' value examination focuses on studying past and present price action to predict the probability of Response Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Response Genetics' price. Additionally, you may evaluate how the addition of Response Genetics to your portfolios can decrease your overall portfolio volatility.